{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:15:29Z","timestamp":1791173729491,"version":"4.1.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,10]],"date-time":"2019-11-10T00:00:00Z","timestamp":1573344000000},"content-version":"vor","delay-in-days":1623,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1093\/annonc\/mdv139","type":"journal-article","created":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T01:32:24Z","timestamp":1426123944000},"page":"1238-1244","source":"Crossref","is-referenced-by-count":117,"title":["Radiosensitization by BRAF inhibitor therapy\u2014mechanism and frequency of toxicity in melanoma patients"],"prefix":"10.1016","volume":"26","author":[{"given":"M.","family":"Hecht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Loquai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Weishaupt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Gutzmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gleisner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Goldinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Berking","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Forschner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Clemens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Grabenbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"M\u00fcller-Brenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Bauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.T.","family":"Eich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Grabbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Schadendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Keikavoussi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Semrau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Fietkau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.V.","family":"Distel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdv139_bb0010","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdv139_bb0015","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv139_bb0020","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdv139_bb0025","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1586\/ern.12.111","article-title":"Melanoma brain metastasis: overview of current management and emerging targeted therapies","volume":"12","author":"Fonkem","year":"2012","journal-title":"Expert Rev Neurother"},{"key":"10.1093\/annonc\/mdv139_bb0030","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1200\/JCO.2012.44.7755","article-title":"Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma","volume":"31","author":"Anker","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv139_bb0035","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00066-014-0698-x","article-title":"Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy","volume":"190","author":"Merten","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1093\/annonc\/mdv139_bb0040","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1684\/ejd.2013.2193","article-title":"Severe radiotherapy-induced extracutaneous toxicity under vemurafenib","volume":"23","author":"Peuvrel","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1093\/annonc\/mdv139_bb0045","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1200\/JCO.2012.44.4265","article-title":"Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy","volume":"31","author":"Satzger","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv139_bb0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00066-013-0474-3","article-title":"Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports","volume":"190","author":"Schulze","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1093\/annonc\/mdv139_bb0055","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1200\/JCO.2013.49.3528","article-title":"Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy","volume":"32","author":"Harding","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv139_bb0060","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/CMR.0000000000000078","article-title":"Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib","volume":"24","author":"Forschner","year":"2014","journal-title":"Melanoma Res"},{"key":"10.1093\/annonc\/mdv139_bb0065","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1684\/ejd.2013.2108","article-title":"Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis?","volume":"23","author":"Reigneau","year":"2013","journal-title":"Eur J Dermatol"},{"key":"10.1093\/annonc\/mdv139_bb0070","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1007\/s00066-014-0707-0","article-title":"Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia","volume":"190","author":"Lang","year":"2014","journal-title":"Strahlenther Onkol"},{"key":"10.1093\/annonc\/mdv139_bb0075","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s11060-013-1127-1","article-title":"Vemurafenib and radiation therapy in melanoma brain metastases","volume":"113","author":"Narayana","year":"2013","journal-title":"J Neurooncol"},{"key":"10.1093\/annonc\/mdv139_bb0080","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1200\/JCO.2013.50.8473","article-title":"Combination of BRAF inhibitors and brain radiotherapy in patients with metastatic melanoma shows minimal acute toxicity","volume":"31","author":"Rompoti","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdv139_bb0085","author":"Institute NC"},{"key":"10.1093\/annonc\/mdv139_bb0090","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1080\/09553000410001724568","article-title":"Technical report. Radiation sensitivity testing by fluorescence in-situ hybridization: how many metaphases have to be analysed?","volume":"80","author":"Keller","year":"2004","journal-title":"Int J Radiat Biol"},{"key":"10.1093\/annonc\/mdv139_bb0095","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.cancergencyto.2004.05.018","article-title":"Cytogenetic instability in young patients with multiple primary cancers","volume":"157","author":"Keller","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1093\/annonc\/mdv139_bb0100","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.radonc.2006.10.012","article-title":"Individual differences in chromosomal aberrations after in vitro irradiation of cells from healthy individuals, cancer and cancer susceptibility syndrome patients","volume":"81","author":"Distel","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mdv139_bb0105","doi-asserted-by":"crossref","first-page":"iv374","DOI":"10.1093\/annonc\/mdu344.8","article-title":"An update on overall survival (OS) and follow-on therapies in BREAK-3, a phase III, randomized trial: dabrafenib (D) vs. dacarbazine (DTIC) in patients (pts) with BRAF V600E mutation-positive metastatic melanoma (MM)","volume":"25","author":"Hauschild","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv139_bb0110","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1186\/s12967-014-0262-6","article-title":"Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose interleukin-2: evaluation of biomarkers of immunologic and therapeutic response","volume":"12","author":"Ridolfi","year":"2014","journal-title":"J Transl Med"},{"key":"10.1093\/annonc\/mdv139_bb0115","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/annonc\/mds292","article-title":"Cutaneous effects of BRAF inhibitor therapy: a case series","volume":"24","author":"Mattei","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdv139_bb0120","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/pcmr.12132","article-title":"Paradoxical oncogenesis: are all BRAF inhibitors equal?","volume":"26","author":"Menzies","year":"2013","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1093\/annonc\/mdv139_bb0125","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1007\/s10637-013-9928-9","article-title":"Genotype-dependent cooperation of ionizing radiation with BRAF inhibition in BRAF V600E-mutated carcinomas","volume":"31","author":"Dasgupta","year":"2013","journal-title":"Invest New Drugs"},{"key":"10.1093\/annonc\/mdv139_bb0130","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.radonc.2010.12.017","article-title":"Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032","volume":"98","author":"Sambade","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1093\/annonc\/mdv139_bb0135","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ejca.2013.11.002","article-title":"Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study","volume":"50","author":"Dummer","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdv139_bb0140","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S1470-2045(12)70431-X","article-title":"Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial","volume":"13","author":"Long","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdv139_bb0145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00008390-200302000-00016","article-title":"A prospective randomized multicentre phase III trial of fotemustine plus whole brain irradiation versus fotemustine alone in cerebral metastases of malignant melanoma","volume":"13","author":"Mornex","year":"2003","journal-title":"Melanoma Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419318125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/26\/6\/1238\/5246510\/mdv139.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:49:34Z","timestamp":1624520974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419318125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0923753419318125"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdv139","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]}}}